FBM add-on open-label treatment was evaluated in 42 patients with severe refractory epilepsy (38 partial epilepsy, 4 Lennox-Gastaut syndrome). FBM was titrated up to the maximal tolerated dose or satisfactory clinical control. Blood parameters of liver and bone marrow function were checked every fortnight. 6 pts showed a seizure reduction greater than 50% and 2 pts were seizure-free over a period ranging 12 to 24 months, 8 pts dropped-out for adverse effects. In 3 cases an increase of serum transaminase and alkaline phosphatase, promptly disappeared after FBM withdrawal, was found.
|Translated title of the contribution||Felbamate: A new evaluation in refractory epileptic patients|
|Number of pages||3|
|Journal||Bollettino - Lega Italiana contro l'Epilessia|
|Publication status||Published - 1999|
ASJC Scopus subject areas
- Clinical Neurology